Introduction
Transforming growth factor beta 1 (TGF-β1) is a fibrogenic cytokine that strongly stimulates the expression of various matrix proteins [1] . While it decreases the proteolytic activity of cells by modulating the expression and secretion of a number of proteases and their regulators including MMPs, TIMPs, plasmin, plasminogen activators and plasminogen activator inhibitor-1 (PAI-1) [2] , it also modulates the expression of integrins on the cell's surface in a manner that facilitates attachment to the newly synthesized matrix [3, 4] . Furthermore, TGF-β is able to induce myofibroblast transformation [5] that is associated with tubulointerstitial fibrosis [6] . Most importantly, it can autoinduce its own production and subsequently amplifies the above actions [7] . Therefore, it is considered the main regulator of the scarring process.
Newly synthesized TGF-β is secreted as a latent, biologically inactive peptide containing the N-terminal sequence latency-associated peptide (LAP). For efficient secretion and correct folding of TGF-β , a partner molecule, latent TGF-β-binding protein (LTBP), is required [8] . When TGF-β is associated with LAP, it is termed the small latent complex (SLC) . If the SLC is disulphide-linked to LTBP by LAP, the resultant complex is termed the large latent complex (LLC) [9] .
Transglutaminase 2 (TG2) is a calcium-dependent enzyme that is believed to have a direct effect on extracellullar matrix (ECM) accumulation via forming a stable and proteolytic resistant ε(γ-glutamyl)-lysine dipeptide cross-link [10] . Studies on TG2 have shown it, like TGF-β1, to be induced in tissue scarring and fibrosis in numerous organs including the lungs, liver and heart, although it is best characterized in kidney scarring [11] [12] [13] . Interestingly, TG2 has been shown to play a role in the activation of TGF-β by cross-linking and recruiting the TGF-β LLC to the ECM for the subsequent proteolytic release of the active 25-kDa TGF-β1 dimer [14] [15] [16] . It has been reported that alterations in TG activity affect levels of latent TGF-β activation in ageing articular chondrocytes [17] . Moreover, macrophages from TG2 knockout mice have impaired phagocytosis function that is related to a deficiency in latent TGF-β activation [18] , while the reduced scar formation seen in the TG2 knockout mouse has been suggested to be TGF-β1-linked [19] . This sheds light on the existence and importance of the TG2-dependent latent TGF-β activation in vivo.
Recent studies from our laboratory have shown TG inhibition to be highly beneficial in treating the scarring and fibrosis associated with experimental diabetic nephropathy (DN) [20] . DN is a major complication of diabetes mellitus (DM) and the most common cause of end-stage kidney disease (ESKD) worldwide [21] . It is clinically characterized by albuminuria and progressive reduction in kidney function that is strongly associated with the structural changes of the kidney. The earliest structural change of DN is kidney hypertrophy. This is then followed by an excessive ECM accumulation in the mesangial matrix, and in the glomerular and tubular basement membranes, leading to glomerulosclerosis and tubulointerstitial fibrosis and subsequent end-stage kidney failure. Both TG2 [13, 22] and TGF-β1 have been strongly implicated in the progression of DN. Although TG inhibition is highly effective at slowing the progression of experimental DN [20] , it remains unclear exactly which mechanism TG inhibition is affecting in DN. Initial investigation suggested that the inhibition of TG2 activity lowered a direct ECM crosslinking, thus reducing deposition rates and generating an ECM more susceptible to proteolysis decay which is consistent with TG2's role in ECM processing [10] . However, given that TG2 is involved in TGF-β activation, many of the beneficial effects of TG inhibition may also be mediated through lower recruitment and activation of the TGF-β LLC.
To address this question, in this study, we aim to use archival tissue from a streptozotocin model of experimental DN treated with TG inhibitor NTU281 [20] and assess the levels of active TGF-β found in both treated and untreated diabetic kidneys. Furthermore, we will then use proximal tubule cells transfected with TG2 to confirm for the first time if simple regulation of TG2 can directly alter TGF-β LLC activation and thus TGF-β activity.
Materials and methods

Synthesis of TG inhibitors
N-benzyloxycarbonyl-L-phenylalanyl-6-dimethylsulphonium-5-oxo-Lnorleucine (NTU281) was synthesized according to published methods [23] . Compound purity was determined by nuclear magnetic resonance and mass spectrometry. Inhibitor efficacy was verified against renal transglutaminases by application of inhibitors at 100 and 500 μm to a 20% kidney homogenate with activity measured using the [ 14 C] putrescine incorporation assay.
Experimental animals and protocol
Application of TG inhibitors to the uninephrectomy model of DN was as previously described [20] . Briefly, 200-250 g male Wistar rats were subjected to uninephrectomy (UNx) of the right kidney. Seven days later, hyperglycaemia was induced by tail vain injection of STZ (35 mg/kg in citrate buffer, pH 4.0). Control animals had a sham operation or UNx with vehicle injection alone. Serum glucose >20 mmol/L at 1 week after STZ was considered diabetic. Blood glucose was controlled between 10 and 25 mmol/L using insulin implants (Research Pack, LinShin, Canada).
The TG inhibitor was applied by a direct intrarenal cannulation from a 2ML4 mini-osmotic pump (Alzet, USA). Animals were divided into four groups: normal, UNx, diabetes with UNx (UNx+DM) and diabetes with UNx treated with NTU281 (UNx+DM+NTU281). At 1, 4 and 8 months after STZ injection, rats were terminated, and kidneys were removed from both diabetic groups (n ≥6) and control (n = 4) groups. All procedures were carried out under licence according to regulations laid down by Her Majesty's Government, UK (Animals Scientific Procedures Act, 1986).
Measurements of glomerular and tubulointerstitial scarring on Masson's trichrome-stained sections as well as measurements of myofibroblasts by immunofluorescence were undertaken using multiphase image analysis as previously described [20] .
Cell lines
Opossum kidney proximal tubular epithelial cells (OK PTECs) (European Collection of Cell Cultures, Cambridge, UK) were cultured in Dulbecco's modified Eagle's medium (DMEM) (BioWhittaker, UK) supplemented with 5% heat-inactivated fetal calf serum, 100 IU/mL penicillin and 100 μg/mL streptomycin (Sigma, UK). Swiss 3T3 fibroblasts, a gift of Dr E. Verderio Edwards [16] , and 1097 mesangial cells were cultured in DMEM supplemented with 10% heat-inactivated fetal calf serum, 100 IU/mL penicillin and 100 μg/mL streptomycin. Mink lung epithelial cells (MLEC) transfected with the PAI-1 promoter containing TGF-β response element linked to luciferase [24] , a gift of Prof. M. Griffin (Aston University, UK), were cultured in DMEM supplemented with 10% heat-inactivated fetal calf serum, 100 IU/mL penicillin, 100 μg/ mL streptomycin and 200 μg/mL Geneticin (Invitrogen, UK). All cultures were maintained at 37°C and in a humidified atmosphere of 5% CO 2 in air.
Construction of pCI-neo-TG2 plasmid, bacteria transformation and restriction mapping of the construct The human 3.3-kb TG2 cDNA fragment was isolated by EcoR I digestion from the pSG5-hTg vector [25] and ligated to the EcoR I-linearized pCIneo (Promega, UK). The construct was introduced into DH5α Escherichia coli using calcium chloride/heat shock plasmid transformation and TG sequence ligation and orientation confirmed by restriction mapping with Xba I.
Transfection
OK cell lines stably expressing TG2 were generated using lipofectin reagent according to the manufacturer's protocol (Invitrogen, UK). Transfections were performed in 100-mm petri dishes with 15-μg pCI-neo or pCI-neo-TG2 plasmids per plate. Clones resistant to 800 μg/mL of geneticin were screened for TG activity.
TG activity assay TG activity was measured by the Ca 2+ -dependent incorporation of [1, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C] putrescine (Amersham Biosciences, UK) into N,N′-dimethylcasein [11] . Results were corrected to units per milligram of protein (1 unit equals 1 nmol of putrescine incorporated per hour at 37°C). Extracellular TG activity was measured by the incorporation of biotinylated cadaverine (Molecular Probes, the Netherlands) into fibronectin (Sigma, UK) as previously described [26] . This assay was performed using 8 × 10 4 cells per well, and cells were incubated for 1 h at 37°C.
TG2 ELISA
Extracellular TG2 antigen was measured using a modified ELISA [16] . This assay was performed using 8 × 10 4 cells per well, and cells were incubated for 2 h at 37°C.
mRNA analysis
Total RNA was exacted from a quarter kidney or 1 × 10 7 cells using Trizol reagent (Invitrogen, UK), and quantitated by optical density at 260 nm. Twenty-five micrograms of total RNA was then run on a 1% (w/v) agarose/MOPS/formaldehyde gel, and the capillary was blotted on to a nylon membrane (Roche Applied Science, UK) and cross-linked with 70 mJ/ cm 2 UV radiation (UV Crosslinker, Amersham Biosciences). This was then probed with [α-
32 P] dCTP random-primed labelled (Prime A Gene, Promega, UK), sequence-specific cDNA probes for TG2 [12] and TGF-β 1, 2 and 3 [27] before exposure to BioMax MS film (Kodak, USA). The resulting autoradiographs were acquired using a Biorad GS-690 densitometer and analysed for volume densitometry using Molecular Analyst version 4 software. Values were then corrected for loading using repeat probings with cyclophilin [28] .
TG2 western blotting
Proteins were separated on an 8% (w/v) polyacrylamide gel and electroblotted onto a Hybond C nitrocellulose membrane (Amersham Life Science, UK). The membrane was blocked with 5% (w/v) non-fat dried milk and 0.1% (v/v) Tween 20 in TBS, and then immunoprobed with an anti-TG2 monoclonal antibody TG100 (Neomarkers, USA) in 1:750 dilution at 4°C overnight. Primary antibody binding was revealed with a goat anti-mouse horseradish peroxidase secondary antibody (Dako, Denmark) in 1:1000 dilution for 1 h at room temperature and visualized using ECL chemiluminescence (Amersham Biosciences, UK). Fluorographs were acquired using a Biorad GS-690 densitometer and analysed for volume densitometry using Molecular Analyst version 4 software. Levels of TG2 protein were normalized to the constitutive expressed protein of β-actin (Abcam, UK).
Mink lung epithelial cell luciferase TGF-β bioassay
Active and total TGF-β were determined using the mink lung epithelial cell luciferase TGF-β bioassay, whereby mink lung epithelial cells are stably transfected with a construct consisting of a PAI-1 promoter that contains the TGF-β response element ligated to the luciferase reporter gene [24] . Plated in a six-well plate, 5 × 10 5 cells/well (single cell culture) or 5 × 10 5 OK TG2 clone 7 and 5 × 10 4 Swiss 3T3 fibroblasts/well (coculture) were cultured overnight. The media was replaced by 1 ml of serum-free DMEM for each well. Cells were then incubated for 24 h, after which time, the media was collected and centrifuged, and the supernatant was recovered for analysis. Cells were released by treatment with 20 mmol/L EDTA/PBS for 40 mins at 37°C, wells were then washed twice with PBS as described by Annes et al [29] prior to acid treatment to release active TGF-β from the ECM and the cell pellets were collected for Lowry assays. Kidney samples were homogenized in STE buffer (0.32 M sucrose, 5 mM Tris and 1 mM EDTA) to make 10% kidney homogenates prior to centrifugation at 30 000×g at 4°C for 30 mins. The supernatant was then filter-sterilized using 4-mm Millex filter units (Millipore, USA). Total TGF-β was determined by activating latent TGF-β using the acid treatment described previously [30] . Samples were diluted with serum-free DMEM and applied to mink lung epithelial cells for 22 h, after which time, the media was removed, and the cells were lysed in 1 × Glo lysis buffer (Promega, UK) and assayed for luciferase activity by the addition of Bright-Glo luciferase substrate (Promega, UK), and run on a Berthold AutoLumat Plus LB 953 luminometer as per manufacturer's instructions.
Statistical analysis
Data are shown as mean ± SEM. Data analyses were performed using one-way ANOVA followed by a Bonferroni post hoc test or a Student's t-test. A probability of 95% (P <0.05) was taken as significant.
Results
Tissue scarring and fibrosis in experimental DN
TG inhibition dramatically reduced the development of tissue scarring and fibrosis in the UNx STZ model of DN as previously described [20] (Table 1) . Briefly, NTU281 significantly reduced increases in serum creatinine (−68%) and albuminuria (−80%) in treated diabetic rats over an 8-month experimental period indicating a preservation of kidney function. This was due to a reduction in glomerulosclerosis (−76.6%) and tubulointerstitial scarring (−68.2%) as a result of lowered accumulation of collagen I, III and IV when compared with controls. In addition, NTU281 reduced numbers of myofibroblasts present, suggesting that TG2 blockade may alter myofibroblast activation [31] (Table 1) . Serum creatinine was calculated from terminal blood samples. Masson's trichrome-stained sections were assessed for glomerular and tubulointerstitial scarring using computerized multiphase analysis. Fibrosis was determined using smooth muscle actin as a marker of myofibroblasts. Data represent mean ± SEM, n = 4-7 per group. Latent TGF-β activation in the diabetic kidney treated with TG inhibitor NTU281
To determine if the benefits of TG inhibition in experimental DN were mediated through reduced TGF-β recruitment and activation, the mink lung cell bioassay was used to assess active TGF-β levels. One month post-DM, active TGF-β levels in the kidney of normal, treated and untreated diabetic groups were similar ( Figure 1A) . However, the amount of total TGF-β (latent + active) in the two diabetic groups increased with the change in the treated group being significant (P <0.05) compared with normal and UNx kidneys ( Figure 1B) . By 4 months, active TGF-β was elevated in both diabetic groups (P <0.05), although slightly higher in the treated group ( Figure 1A , P = 0.05). This was in line with the changes in total TGF-β levels ( Figure 1B , P <0.05), although there was a lower percentage of total TGF-β activated in the TG inhibitor-treated diabetic kidneys than in the untreated ( Figure 1C , P < 0.05). By 8 months, levels of active TGF-β in both diabetic groups were still higher than the normal and UNx ( Figure 1A , P <0.05), but importantly, active TGF-β in the diabetic kidney was 33.6% greater than in those receiving TG inhibition therapy ( Figure 1A , P < 0.05). The level of total TGF-β in the TG inhibitor-treated kidney remained comparable to the normal, while in the untreated diabetic kidney, total TGF-β levels doubled ( Figure 1B , P < 0.05). The percentage of total TGF-β activated in the treated diabetic kidney was higher than the untreated ( Figure 1C , P <0.05).
Synthesis of TGF-β isoforms in the diabetic kidney
TGF-β1 is by far the major isoform being produced in the kidney. TGF-β2 and TGF-β3 were only detected in the kidneys with advanced DN when the BioMax MS films had been exposed for an extremely long time (8 days); even under such circumstances, the bands representing TGF-β2 and TGF-β3 were still not discrete (data not shown). Subsequently, changes in TGF-β in the diabetic kidney were primarily caused by TGF-β1 with TGF-β2 and TGF-β3 contributing a minor component. At 1 and 4 months post-induction of diabetes, there were higher mean levels of TGF-β1 mRNA in the diabetic kidneys compared with the normal and uninephrectomy, but it was not significant. By 8 months, the untreated diabetic kidney TGF-β1 mRNA level had increased 3.8-and 9.4-fold compared with normal and UNx, respectively ( Figure 1D , P <0.05). However, the treated diabetic kidney had a TGF-β1 mRNA level 43.0% lower than the untreated ( Figure 1D , P <0.05) suggesting that TG inhibition reduced the transcriptional expression of TGF-β1 in the diabetic kidney by 8 months.
To determine if the effect of NTU281 was a non-specific effect on transcription factors or TGF-β1-related cell signal pathways rather than via TG2, we exposed 1097 mesangial cells to NTU281 for 24 h and measured changes in TGF-β1 mRNA levels. Even using a double IC 50 (250 μM), there was no effect on TGF-β1 mRNA (Supplementary Figure 1 .)
TG2 overexpressing OK proximal tubular epithelial cells
The reduction in TGF-β mRNA in response to TG inhibition in the diabetic kidney made interpretation of the mechanism(s) of the fall in active TGF-β in this model difficult to interpret. Therefore, to address this, we transfected OK cells with the human TG2 cDNA [25] in the pCIneo expression vector (Promega). Forty-six clones were subcultured and screened for cellular TG activity using the 14 C putrescine incorporation assay. Three clones that had 2-(TG2 18), 5.5-(TG2 21) and 7-fold (TG2 7) increases in normal TG activity were selected for use in this study. Another clone transfected with the empty pCIneo vector was used as a transfection control. The increased TG activity was related to the overexpression of TG2 using northern blotting ( Figure 2A ) and western blotting ( Figure 2B ) analysis. Extracellular TG activity and TG2 antigen were assessed to confirm cell export post-transfection given the requirement for extracellular TG in the latent TGF-β activation process ( Figure 2C and D) .
Measurement of latent TGF-β activation in TG2 overexpressing OK clones
Surprisingly, compared with the transfection control, TG2-overexpressing clones 18, 21 and 7 all showed decreased levels of active TGF-β ( Figure 3A) . The levels of ECM-bound TGF-β were also lower in clone 21 and 7 ( Figure 3B ), contributing towards lower levels of total TGF-β in both the medium and ECM in these two clones ( Figure 3C ) suggesting variation in the amount of TGF-β synthesized in these cells. Calculation of the percentage of total TGF-β converted to the active form showed significantly lower percentages of total TGF-β activated in the clones regardless of TG2 overexpression ( Figure 3D ). Given TG2's role in latent TGF-β activation is to recruit the LLC in the ECM by cross-linking LTBP to the ECM, the percentage of total TGF-β incorporated into the ECM was also calculated. However, there was no change in percentage of ECM-bound TGF-β between the transfection control and the TG2-overexpressing clones ( Figure 3E ).
Expression of TGF-β1, TGF-β2 and TGF-β3 in the OK clones
In all the OK clones, TGF-β1 and TGF-β2 were the predominant isoforms being synthesized at the mRNA level ( Figure 4A) . Surprisingly, all TG-overexpressing cells had lower TGF-β1 mRNA than the transfection control, with the higher the TG2 expression, the lower the TGF-β1 mRNA. The level of TGF-β2 was different from transfection control in clone 18 and 7, but did not relate to TG2 activity as for TGF-β1. TGF-β3 transcript was only really detectable after a very long exposure, and then only in TG2 OK clone 18 which was slightly overloaded on the blot ( Figure 4A ). This data is consistent with the previous observation that the OK clones express decreasing amounts of TGF-β as TG2 increases. Fig. 1 . TGF-β activation in NTU281-treated diabetic kidneys. Active TGF-β (A), total TGF-β (B), percentage of total TGF-β activated (C) and TGFβ1 mRNA levels (D) in kidneys at 1, 4 and 8 months post-DM. Supernatant from a 10% kidney homogenate was filter-sterilized, and biological activity of TGF-β in the supernatant was determined using the mink lung TGF-β bioassay. Total TGF-β was converted to a biologically active form for analysis by acid activation. Percentage activation was calculated by expressing the level of active TGF-β as a percentage of total TGF-β (e.g. acid-activated). TGF-β1 mRNA was measured by northern blot analysis with densitometer normalized to the housekeeping gene cyclophilin. Data represent mean ± SEM, n = 4-7 per group. Significance (P <0.05) is indicated in comparison with normal (a), uninephrectomy (b), diabetic (c) and NTU281-treated diabetic (d). Fig. 2 . Characterization of TG2-overexpressing OK cell clones. TG2 mRNA was detected using northern blot analysis, quantified using densitometry and normalized to the constitutively expressed mRNA of cyclophilin (A). TG2 protein levels were detected using western blot analysis, quantified using densitometry and normalized to constitutively expressed β-actin (B). Extracellular TG2 antigen (C) was measured by surface binding of TG2 antibody CUB7402 and extracellular TG activity (D) by the incorporation of biotin cadaverine into fibronectin. Data represent mean ± SEM. Analysis performed in triplicate on three or more separate occasions.
Does TG2 influence TGF-β1 transcription via its intra-or extracellular action?
To gain some basic understanding of why elevated TG2 would reduce TGF-β1 mRNA levels, the initial investigation was to determine if this was due to the intracellular (TG2 can act as a GTPase) or extracellular actions of TG2 studies. Studies were therefore repeated in TG2-transfected 1097 mesangial cells which will not export excess TG2 no matter how high intracellular TG2 levels are raised. In 1097 cell clones, expressing 2-fold (TG2 34), 5-fold (TG2 36) and 14-fold (TG2 37) TG activity demonstrated no affect on TGF-β1 mRNA levels (Supplementary Figure 2) demonstrating that any influence of TG2 on TGF-β1 mRNA levels must be via an extracellular (and therefore posttranslational modification action) of TG2. Fig. 3 . TGF-β activation levels in TG2-overexpressing OK cell clones. Active TGF-β (A), total ECM-bound TGF-β (B), total TGF-β (C), percentage of total TGF-β activated (D) and percentage of TGF-β bound to ECM (E) in TG2-overexpressing OK cell clones. Cells were cultured in serum-free DMEM for 24 h. Condition medium was collected. Cells were released using EDTA, and ECM laid down by cells was treated with acid to release the active TGF-β dimer for assessment of the ECM-bound TGF-β. Biological activity of TGF-β in the medium was determined using the mink lung TGF-β bioassay. Total TGF-β in the medium was converted to a biologically active form for analysis by acid activation. Data represent mean ± SEM. Analysis was performed in triplicate on three or more separate occasions.
Can active TGF-β1 feedback on its own synthesis in proximal tubular cells?
OK cells were exposed to active TGF β1 ranging from 500 pg to 10 ng/ml, and the level of TGF β1mRNA was measured (Supplementary Figure 3) . Up to 500 pg/mL, there was no change in TGF-β1 mRNA; however, there was a small but significant increase at 1 ng/mL with a substantial 4.6-fold increase at 10 ng/mL.
TGF-β1 systems in OK proximal tubular epithelial cells
There was surprisingly no change in the percentage of TGF-β activated between control and TG2-overexpressing cells. To verify that OK PTEC contained all the standard components of the TGF-β recruitment/activation system, Western blot analysis of LTBP-1 was performed. It showed a complete lack of 180-kDa immunoreactive LTBP-1 in these cells in culture ( Figure 5 ). LTBP-1 is the key molecule in the TG-dependent latent TGF-β activation. A single OK tubular epithelial cell culture is therefore not suitable to determine if latent TGF-β activation in the kidney is TG2-dependent, as a source of LTBP-associated TGF-β is required.
TG-overexpressing OK cells co-cultured with Swiss 3T3 fibroblasts
To compensate for the failure of OK cells to generate the LLC, we adopted a co-culture approach with the TG2-overexpressing OK cells being cultured with LLCgenerating Swiss 3T3 fibroblasts [16] . The level of endogenous cellular TG activity in Swiss 3T3 fibroblasts was 7-fold higher than the OK pCI-neo transfection control, but lower than the TG2 OK clone 7 ( Figure 6A) . A co-culture using a 1:10 ratio of fibroblasts to OK cells subsequently reduced the difference of cellular TG activity between the two groups from 10-fold to 5.4-fold ( Figure 6B ). However, 3T3 cells have little extracellular TG activity ( Figure 6C ), so the overall 3.5-fold difference in extracellular TG activity (which is important for TGF-β activation) between control and TG2-overexpressing cell line TG2-7 remained almost unchanged in co-culture with fibroblasts ( Figure 6D) .
To verify the effect of co-culture on TGF-β1 found in the ECM, cells were removed, and the mink lung bioassay was used to assess the total ECM TGF-β. Low levels of ECMbound TGF-β ( Figure 7) were found in single cultures of either OK cells (no LLC) or 3T3 fibroblasts (little extra cel- Fig. 4 . Northern blot analysis of TGF-β 1, TGF-β2 and TGF-β3 mRNA in TG2-overexpressing OK cell clones. Autoradiographs from northern blots probed for TGF-β1, TGF-β2 and TGF-β3 (A). Levels of TGF-β1 (B) and TGF-β2 (C) expression were quantified using volume densitometry and normalized to the housekeeping gene, cyclophilin. Data represent mean ± SEM, n = 3. lular TG2); however, when co-cultured, ECM-bound TGF-β was 57-fold higher than OK cells cultured alone.
Latent TGF-β activation in OK clones co-cultured with Swiss 3T3 fibroblasts Compared with OK transfection control cells, there was a 21% increase in ECM-bound TGF-β in TG2-overexpressing clone TG2-7 when LLC was supplied by co-culture with 3T3 fibroblasts ( Figure 8A , P < 0.05). This led to a 20% increase in active TGF-β levels in the media of the TG2-overexpressing cells ( Figure 8B ).
Discussion
In this study, elevated TGF-β is associated with the development of experimental DN. The beneficial effects of TG inhibition in ameliorating renal scarring are associated with a lower level of active TGF-β and a reduction in total renal TGF-β that is mRNA-dependent. There is no evidence for non-specific effects of NTU281 in these changes. While benefits of TG inhibition may partly occur through lower TGF-β, it is difficult to unravel any influence of TG activity on TGF-β activation in vivo as DN is highly complex with numerous interconnected growth factor and cytokine signalling pathways [32, 33] that are responsive to changing ECM feedback and inflammation [34] .
To address this, we used a cell culture model using OK proximal tubular cells (main TG2 source in diabetic kidney) transfected to produce increasing levels of TG2 to correlate TGF-β activation with changes in TG2. However, this produced data opposite to that predicted from in vivo studies as increasing TG2 led to an mRNA-dependent reduction in active and total TGF-β (including percentage of total TGF-β activated). While these data correlate with published data using TG2-overexpressing cells that link increasing TG2 activity with a reduction in collagen I, III and IV mRNA expression [10] , it suggests that changes in TG2, far from causing increased TGF-β1 activation as hypothesized, actually shut TGF-β1 synthesis down. This is due to an extracellular action of TG2 (e.g. post-translational modification of ECM proteins feeding back) rather than an intracellular action (TG2 can act as a GTPase) as TG2 overexpression in mesangial cells, which do not increase TG2 export irrespective of intracellular levels, had no change in TGF-β1 mRNA.
To understand why OK cells did not have an increased conversion of latent to activated TGF-β despite elevation of TG2, we tested if they had all of the components of the proposed TG2-mediated TGF-β activation pathway, i.e. LAP and LTBP. Western blots for LTBP showed that these cells do not produce LTBP and thus cannot form the LLC that is the starting point for the TG2-dependent pathway. This is consistent with another study that looked for LTBP in tubules [35] . It would therefore be impossible for TG2 to affect TGF-β activation.
Subsequently, a co-culture system using TG2-overexpressing OK cells (export large amounts of TG2) with 3T3 fibroblasts (high LLC [16] and low extracellular TG2) was established. By co-culturing these cells, we established a model of the in vivo system in renal fibrosis. In a high TG2 environment (i.e. co-culture with TG2 OK clone 7), we detected more ECM-bound TGF-β and more active TGF-β in the media than in co-culture with control cells. Of note is that, even though 3T3 fibroblasts make considerable LLC, they have almost no detectable active TGF-β when cultured alone (30× less than co-culture with TG2 7 cells) or ECM-bound TGF-β (<8× less than when cultured with TG2 7) which likely reflects their low extracellular TG2 activity. Importantly, while TGF-β1 can have a positive feedback on its own production [7] , in OK cells, this does not occur until doses are many times higher than we report here and thus would not contribute to higher TGF-β activity seen in the co-culture system.
Taking all these data together, in tubular epithelial cells, elevated cellular production of TG2 results in lower synthesis of TGF-β1; however, the high TG2 is able to recruit and activate more TGF-β produced by other cells. Such a feedback system offers distinct advantages to cells in that activation of TGF-β requires a coordinated cell response offering an important regulatory step; furthermore, it helps target activation of TGF-β1 in the wound response to damaged areas (that are normally TG2 positive) as well as ensuring that cells producing TGF-β1 do not instigate a potentially harmful autocrine response.
Central to the hypothesis of a TG2-controlled TGF-β activation pathway is the trafficking of TG2 to the outside of the cell to enable cross-linking of the LLC to the ECM. TG2 has classically been viewed as a cytoplasmic enzyme as it lacks a leader sequence [36] . However, recent studies have demonstrated significant staining on the cell surface and in the ECM, especially under 'stressed' [37, 38] and fibrotic conditions confirming TG2 can be exported [13, 22, [39] [40] [41] . In vitro studies have clearly demonstrated that this leakage is not due to cell damage but to a controlled export mechanism dependent on an intact N-terminal β-sandwich domain and the active site conformation of the enzyme [42] . Apart from the TG2-dependent latent TGF-β activation pathway pro- Fig. 6 . Transglutaminase activity in single (A) and OK cell/fibroblast co-culture (B) systems. TG activity was measured using the 14 C putrescine incorporation assay both in single cultures of the TG2 OK clone 7 and Swiss 3T3 fibroblasts (A) and then in co-culture when plated with a 10:1 ratio of TG2 7 (or transfection control) to Swiss 3T3 fibroblasts (B). Repeat measurements of extracellular TG activity were then made using biotin cadaverine incorporation in both single (C) and co-culture (D) systems. Numbers in parentheses indicate fold increase in TG activity compared with the transfection control. Data represents mean ± SEM, n = 3. posed by Rifkin [14] , which we demonstrate can be used to regulate TGF-β activation by changes in TG2 levels, there are other latent TGF-β activation mechanisms that have been described. These are the integrin and thrombospondin-1 (TSP-1)-dependent pathways. Integrin α V β 6 is a matrix receptor that binds LAP and induces conformational changes which subsequently activate latent TGF-β [43] . The β 6 subunit is present in renal tubular epithelium [44] but is absent in the glomerulus [45] . In β 6 −/− kidneys subjected to unilateral ureteral obstruction, a reduction in active TGF-β in tubular epithelial cells is evident [45] . In addition to the integrins, TSP-1 is believed to have a major role in latent TGF-β activation in vivo [46] . In vitro, it is able to activate LLC or SLC [47] by binding to the LAP causing a conformational change that subsequently leads to the liberation of the mature TGF-β [48] . Tubular epithelial cells generate TSP-1 [49] with upregulation associated with increased TGF-β bioactivity in pathological environments [49, 50] . In mesangial cells, TSP-1 is one of the glucose-regulated genes [51] and implicated as the key latent TGF-β activator in mesangial cells [52, 53] . It is likely that all these potential mechanisms may be involved in the latent TGF-β activation in the diabetic kidney and contribute to the active TGF-β conversion to varying extents. Of note is that the mechanisms requiring ECMbound LLC (mediated by plasmin and α V β 6 , respectively) can be affected by the self-limiting feedback loop formed by the plasmin-TGF-β system or the loss of the tubules as the disease progresses (Supplementary Figure 4) . TGF-β is able to induce the expression of PAI-1, the main inhibitor of plasminogen activation, which leads to a decrease in the generation of plasmin [54] . PAI-1 is increased in diabetic kidneys of humans and animals [55, 56] , and therefore, theoretically plasmin could become a limiting factor. A similar feedback loop also applies to the mechanism mediated by α V β 8 as TGF-β stimulates TIMP that can decrease the required MMP activity [57] . In addition, tubular atrophy may result in a reduction in integrin α V β 6 . So, one could hypothesize that changes in all these pathways may contribute to the varying levels of TGF-β activation as DN progresses, explaining why the data in the DN model varies from that described in our in vitro model and why the benefits of TG inhibition on TGF-β activation may be more evident in the latter stages of disease. However, it should not be overlooked that, even at 4 months, despite elevated total and active TGF-β1, the percentage of total TGF-β1 activated in the NTU281-treated group is reduced, indicating that TG inhibition may be having some effect despite increased TGF-β1 production at this stage.
Although TG inhibition then appeared to have a little effect on the percentage of TGF-β activated towards the end of the in vivo study, this does not mean it is not essential to the process. TG inhibition throughout the whole experimental period would theoretically cause a decrease in matrix-bound LLC that is believed to be essential in the progressive process of glomerulosclerosis and tubulointerstitial fibrosis. The prevention of TG-mediated recruitment of the LLC to the ECM means that the LLC is then lost from the kidney either in the urine [58] or systemic circulation. Therefore, TG inhibition not only reduces latent TGF-β activation during the early development of DN but keeps matrix-bound LLC, a limiting factor in activation of TGF-β in advanced DN.
From this study, we can therefore conclude that, both in vivo and in controlled in vitro systems, TG2 modulation is tied to changes in active TGF-β1. While raising and lowering TG2 levels have the ability to directly alter TGF-β1 activation by the recruitment of the LLC as hypothesized, there also appears to be a link between TG2 levels and TGF-β1 transcription, the nature of which is not clear from the data presented here, although it is clearly linked to an extracellular effect of TG2 and thus post-translational effect on a target protein.
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